NRIX

Nurix Therapeutics Inc

Feb 03 • 03:10PM ET

16.75

-0.34 -2.02 %

Healthcare • Biotechnology • USA • NASD

Peers: FATE CRSP BMRN EDIT NTLA TVRD BLUE KPTI RGNX PTGX

| Held by: VTI IWM ARKG XBI VXF IWN IBB VTWO SCHA IWC

Index	RUT	P/E	-	EPS (ttm)	-3.04	Insider Own	1.53%	Shs Outstand	101.81M	Perf Week	-13.73%
Market Cap	1.72B	Forward P/E	-	EPS next Y	-3.00	Insider Trans	-4.56%	Shs Float	101.27M	Perf Month	-7.28%
Enterprise Value	1.18B	PEG	-	EPS next Q	-0.76	Inst Own	85.75%	Short Float	15.01%	Perf Quarter	29.40%
Income	-264.46M	P/S	20.51	EPS this Y	-2.35%	Inst Trans	-6.77%	Short Ratio	9.50	Perf Half Y	48.45%
Sales	83.98M	P/B	3.16	EPS next Y	4.04%	ROA	-38.38%	Short Interest	15.20M	Perf YTD	-11.73%
Book/sh	5.29	P/C	2.90	EPS next 5Y	6.16%	ROE	-49.63%	52W High	22.50 -25.58%	Perf Year	-15.04%
Cash/sh	5.77	P/FCF	-	EPS past 3/5Y	6.31% -2.04%	ROIC	-44.70%	52W Low	8.18 104.71%	Perf 3Y	35.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	29.55% 36.35%	Gross Margin	77.55%	Volatility	8.39% 6.36%	Perf 5Y	-57.40%
Dividend TTM	-	EV/Sales	14.11	EPS Y/Y TTM	-5.27%	Oper. Margin	-340.16%	ATR (14)	1.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.02	Sales Y/Y TTM	53.95%	Profit Margin	-314.90%	RSI (14)	41.01	Recom	1.06
Dividend Gr. 3/5Y	- -	Current Ratio	7.02	EPS Q/Q	-10.16%	SMA20	-8.86%	Beta	1.96	Target Price	30.00
Payout	-	Debt/Eq	0.10	Sales Q/Q	2.21%	SMA50	-8.63%	Rel Volume	0.36	Prev Close	17.09
Employees	317	LT Debt/Eq	0.10	Earnings	Jan 28 AMC	SMA200	31.91%	Avg Volume	1.60M	Price	16.75
IPO	Jul 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.86% 1.33%	Trades		Volume	505,336	Change	-2.02%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$36
Nov-24-25	Resumed	Truist	Buy	$30
Oct-21-25	Initiated	Mizuho	Outperform	$24
Mar-17-25	Initiated	Leerink Partners	Market Perform	$16
Dec-10-24	Initiated	BTIG Research	Buy	$35
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$35
Oct-24-24	Initiated	UBS	Buy	$35
Oct-11-24	Initiated	Jefferies	Buy	$41
Sep-06-24	Resumed	Robert W. Baird	Outperform	$26
Jul-31-24	Initiated	Truist	Buy	$36
Jun-26-23	Resumed	Oppenheimer	Outperform	$25
Mar-09-23	Initiated	Barclays	Overweight	$20
Feb-28-23	Initiated	Oppenheimer	Outperform	$25
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight	$11
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$25
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$28
Dec-29-21	Initiated	H.C. Wainwright	Buy	$62
Oct-14-21	Initiated	SVB Leerink	Outperform	$50
Jun-04-21	Resumed	Robert W. Baird	Outperform	$45 → $46
Apr-30-21	Resumed	Piper Sandler	Overweight	$60

Show Previous Ratings

Feb-02-26 10:02PM	Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory (Insider Monkey)
09:29AM	Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts (Insider Monkey)
Jan-30-26 09:47AM	H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX) (Insider Monkey) -6.08%
Jan-28-26 05:35PM	Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.93%
04:01PM	Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
10:00AM	Loading…
Jan-23-26 10:00AM	Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
Jan-14-26 10:52AM	Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff (PR Newswire)
Jan-12-26 07:00AM	Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases (GlobeNewswire)
Jan-05-26 07:00AM	Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-25 09:03AM	Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Dec-21-25 09:57AM	Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT (Insider Monkey)
Dec-09-25 02:23PM	Nurix (NRIX) Soars 18.7% on Encouraging Blood Cancer Treatment Trial (Insider Monkey) -8.94%
Dec-08-25 04:07PM	Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent? (Investor's Business Daily) +18.68%
08:00AM	Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenstrom Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (GlobeNewswire)
09:30AM	Loading…
Dec-06-25 09:30AM	Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition (GlobeNewswire)
Dec-01-25 07:00AM	Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (GlobeNewswire)
Nov-25-25 07:00AM	Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-10-25 07:00AM	Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors (GlobeNewswire)
Nov-07-25 09:00AM	Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling (GlobeNewswire)
Nov-03-25 09:00AM	Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-30-25 07:00AM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +9.23%
Oct-27-25 07:00AM	Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock (GlobeNewswire) +8.03%
Oct-22-25 07:20AM	Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock (GlobeNewswire)
06:00AM	Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia (GlobeNewswire)
Oct-18-25 03:00AM	Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress (GlobeNewswire)
Oct-17-25 09:00AM	Precision Oncology Approaches Drive $312B Market Transformation (PR Newswire)
Oct-09-25 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +8.82% -10.13%
04:01PM	Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Sep-25-25 09:29AM	Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks)
07:00AM	Loading…
Sep-17-25 07:00AM	Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis (GlobeNewswire)
Sep-11-25 08:05AM	KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Aug-28-25 04:01PM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-15-25 10:10AM	Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright (TipRanks)
Jul-09-25 04:01PM	Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire) +7.94%
Jul-07-25 07:00AM	European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia (GlobeNewswire)
07:00AM	European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenstrom Macroglobulinemia (GlobeNewswire)
Jul-03-25 10:00AM	Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
09:55AM	Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know (Zacks)
Jul-01-25 10:29AM	Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock? (Zacks)
Jun-17-25 05:15PM	Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Jun-13-25 04:01PM	Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-12-25 07:00AM	Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM) (GlobeNewswire) -5.30%
07:00AM	Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenstrom Macroglobulinemia (WM) (GlobeNewswire)
Jun-06-25 07:00AM	Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025) (GlobeNewswire)
Jun-03-25 09:09AM	Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last? (Zacks)
Jun-02-25 08:12AM	Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout (Benzinga) +14.21%
07:00AM	Sanofi Exercises License Extension Option to Nurix's STAT6 Program (GlobeNewswire)
May-28-25 07:00AM	Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-25 04:00PM	Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-15-25 07:00AM	Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-14-25 09:30AM	Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma (GlobeNewswire)
May-13-25 08:48AM	Why Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy Now (Insider Monkey)
Apr-28-25 04:00PM	Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs (GlobeNewswire)
Apr-25-25 01:00PM	Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets (GlobeNewswire)
Apr-17-25 05:07PM	Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential (Seeking Alpha)
07:00AM	Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions (GlobeNewswire)
Apr-11-25 04:01PM	Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.77%
Apr-08-25 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-03-25 09:08AM	NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program (Zacks) -7.64%
Apr-02-25 10:00AM	Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +8.69%
07:00AM	Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases (GlobeNewswire)
Mar-31-25 05:15PM	Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -11.87%
Mar-27-25 05:20PM	Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-25-25 04:30PM	Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting (GlobeNewswire) -5.70%
Mar-17-25 07:00AM	Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenstrom Macroglobulinemia (GlobeNewswire)
07:00AM	Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenstr m Macroglobulinemia (GlobeNewswire)
Mar-14-25 04:00PM	Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-13-25 04:00PM	Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors (GlobeNewswire) -9.28%
Mar-04-25 07:00AM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-25 04:01PM	Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-04-25 07:00AM	Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-28-25 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:00PM	Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jan-22-25 07:00AM	Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer (GlobeNewswire)
Jan-13-25 07:00AM	Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases (GlobeNewswire)
Jan-06-25 07:00AM	Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-24 07:00AM	Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia (GlobeNewswire)
Dec-11-24 12:05PM	Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers? (Insider Monkey)
Dec-09-24 06:00PM	Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting (GlobeNewswire) +6.78%
Dec-04-24 01:10PM	Why Is Nurix Therapeutics, Inc. (NRIX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-02-24 07:00AM	Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-25-24 07:00AM	Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-20-24 04:00PM	Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia (GlobeNewswire)
Nov-17-24 10:30AM	Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 (GlobeNewswire)
Nov-05-24 09:00AM	Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-24 07:00AM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-21-24 04:00PM	Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit (GlobeNewswire)
05:45AM	Nurix Therapeutics NX-5948 shows promise in Waldenstroms macroglobulinaemia trial (Clinical Trials Arena)
Oct-19-24 08:00AM	Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia (GlobeNewswire)
Oct-16-24 04:35PM	Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur (GlobeNewswire)
Oct-11-24 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +8.10% +6.47%
04:00PM	Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-09-24 07:00AM	Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology (GlobeNewswire)
Sep-30-24 07:00AM	Nurix Therapeutics Announces Presentations at Discovery on Target Conference (GlobeNewswire)
Sep-24-24 09:15AM	Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase (PR Newswire)
Sep-06-24 07:00AM	Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit (GlobeNewswire)
Sep-05-24 12:01AM	Nurix Therapeutics, Inc. (NRIX): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rape, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
van Houte Hans	Chief Financial Officer	Jan 30 '26	Option Exercise	0.00	11,496	0	49,088	Jan 30 08:39 PM
van Houte Hans	Chief Financial Officer	Jan 30 '26	Sale	16.60	3,661	60,767	45,427	Jan 30 08:39 PM
Ring Christine	Chief Legal Officer	Jan 30 '26	Option Exercise	0.00	10,534	0	61,431	Jan 30 08:38 PM
Ring Christine	Chief Legal Officer	Jan 30 '26	Sale	16.60	4,421	73,381	57,010	Jan 30 08:38 PM
Hansen Gwenn	Chief Scientific Officer	Jan 30 '26	Option Exercise	0.00	11,816	0	88,567	Jan 30 08:36 PM
Hansen Gwenn	Chief Scientific Officer	Jan 30 '26	Sale	16.60	4,895	81,249	83,672	Jan 30 08:36 PM
Ring Christine	Chief Legal Officer	Jan 20 '26	Option Exercise	1.86	3,760	6,994	54,657	Jan 20 07:57 PM
Ring Christine	Chief Legal Officer	Jan 20 '26	Sale	18.42	3,760	69,273	50,897	Jan 20 07:57 PM
Ring Christine	Chief Legal Officer	Dec 18 '25	Option Exercise	1.86	3,760	6,994	54,657	Dec 18 06:08 PM
Ring Christine	Chief Legal Officer	Dec 18 '25	Sale	17.90	3,760	67,314	50,897	Dec 18 06:08 PM
CHRISTINE RING	Officer	Dec 18 '25	Proposed Sale	18.21	7,520	136,939		Dec 18 04:21 PM
Ring Christine	Chief Legal Officer	Nov 24 '25	Option Exercise	1.86	37,600	69,936	88,497	Nov 24 06:06 PM
Ring Christine	Chief Legal Officer	Nov 24 '25	Sale	17.07	37,600	641,697	50,897	Nov 24 06:06 PM
CHRISTINE RING	Officer	Nov 24 '25	Proposed Sale	16.76	37,600	630,176		Nov 24 04:27 PM
van Houte Hans	Chief Financial Officer	Nov 03 '25	Sale	12.56	6,284	78,931	37,592	Nov 03 07:14 PM
JOHANNES VAN HOUTE	Officer	Nov 03 '25	Proposed Sale	12.94	6,284	81,315		Nov 03 04:27 PM
van Houte Hans	Chief Financial Officer	Oct 30 '25	Option Exercise	0.00	11,494	0	47,006	Oct 30 06:06 PM
van Houte Hans	Chief Financial Officer	Oct 30 '25	Sale	12.80	3,130	40,054	43,876	Oct 30 06:06 PM
Ring Christine	Chief Legal Officer	Oct 30 '25	Option Exercise	0.00	10,532	0	54,541	Oct 30 06:02 PM
Ring Christine	Chief Legal Officer	Oct 30 '25	Sale	12.80	3,644	46,631	50,897	Oct 30 06:02 PM
Hansen Gwenn	Chief Scientific Officer	Oct 30 '25	Option Exercise	0.00	11,815	0	80,838	Oct 30 06:01 PM
Hansen Gwenn	Chief Scientific Officer	Oct 30 '25	Sale	12.80	4,087	52,300	76,751	Oct 30 06:01 PM
GREGORY JULIA P	Director	Sep 17 '25	Option Exercise	1.86	10,750	19,995	10,750	Sep 17 06:58 PM
van Houte Hans	Chief Financial Officer	Aug 01 '25	Sale	11.03	5,402	59,598	35,512	Aug 01 05:09 PM
JOHANNES VAN HOUTE	Officer	Aug 01 '25	Proposed Sale	11.26	5,402	60,827		Aug 01 04:28 PM
van Houte Hans	Chief Financial Officer	Jul 30 '25	Option Exercise	0.00	11,494	0	45,218	Jul 30 06:49 PM
van Houte Hans	Chief Financial Officer	Jul 30 '25	Sale	12.01	4,304	51,695	40,914	Jul 30 06:49 PM
Ring Christine	Chief Legal Officer	Jul 30 '25	Option Exercise	0.00	10,532	0	47,850	Jul 30 06:49 PM
Ring Christine	Chief Legal Officer	Jul 30 '25	Sale	12.01	3,841	46,134	44,009	Jul 30 06:49 PM
Hansen Gwenn	Chief Scientific Officer	Jul 30 '25	Option Exercise	0.00	11,815	0	73,331	Jul 30 06:48 PM
Hansen Gwenn	Chief Scientific Officer	Jul 30 '25	Sale	12.01	4,308	51,743	69,023	Jul 30 06:48 PM
van Houte Hans	Chief Financial Officer	May 02 '25	Sale	11.33	6,198	70,243	33,724	May 02 06:18 PM
JOHANNES VAN HOUTE	Officer	May 02 '25	Proposed Sale	11.16	6,198	69,170		May 02 04:22 PM
Hansen Gwenn	Chief Scientific Officer	Apr 30 '25	Option Exercise	0.00	8,956	0	64,893	Apr 30 07:35 PM
Hansen Gwenn	Chief Scientific Officer	Apr 30 '25	Sale	11.50	3,377	38,841	61,516	Apr 30 07:35 PM
Ring Christine	Chief Legal Officer	Apr 30 '25	Option Exercise	0.00	7,674	0	40,212	Apr 30 07:35 PM
Ring Christine	Chief Legal Officer	Apr 30 '25	Sale	11.50	2,894	33,286	37,318	Apr 30 07:35 PM
van Houte Hans	Chief Financial Officer	Apr 30 '25	Option Exercise	0.00	8,636	0	42,360	Apr 30 07:35 PM
van Houte Hans	Chief Financial Officer	Apr 30 '25	Sale	11.50	2,438	28,041	39,922	Apr 30 07:35 PM
van Houte Hans	Chief Financial Officer	Mar 03 '25	Sale	14.49	5,825	84,388	33,724	Mar 03 05:29 PM
JOHANNES VAN HOUTE	Officer	Mar 03 '25	Proposed Sale	15.45	5,825	89,996		Mar 03 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NRIX

Nurix Therapeutics Inc

Upgrade your FINVIZ experience